Aerobic glycolysis is a key characteristic of cancer cells that significantly affects the metabolic pathways and metabolites of transformed cells. While these changes enable the unregulated growth and survival of cancer cells, they may also be used for selective chemotherapeutic targeting. One such defining change is the increased production of ROS and the subsequent additional oxidative stress placed on cancer cells (1), which is thought to be play a key role in the maintenance of the tumour phenotype (2-4).
antioxidant machinery of cancer cells is thought to operate at near capacity due to higher basal ROS and upregulated ROS-mediated signalling, which potentially makes them vulnerable to agents that cause additional oxidative pressure, providing a mechanism by which cancer cells can be selectively targeted (6) . In line with this hypothesis, a range of chemotherapeutics have been proposed to function by increasing the oxidative stress in cancer cells (7) (8) (9) (10) , and several screens aimed at identifying compounds that selectively inhibit the growth of transformed cells have converged on compounds that act to increase oxidative pressure by reducing glutathione levels (11) (12) (13) . Compounds such as phenyl isocyanate (12), 2-methoxyoestradiol (14) , and piperlongumine (11) selectively kill cancer cells (at doses of 5-20 µM) by interfering with ROS homeostasis pathways.
Cribrostatin 6 is an imidazo [5,1-a] isoquinoline isolated from the marine sponge Cribrochalina sp (15) , which has been shown to be cytotoxic in several cancer cell lines, triggering apoptosis by elevating intracellular ROS (16) . The mechanism of this process is likely to be similar to other quinones, which undergo bioreduction in cells to the corresponding semiquinone, which then reacts with molecular oxygen to generate superoxide (8) . Cancer cells treated with cribrostatin 6 also showed an elevation of antioxidant transcripts, including heme oxygenase 1, several ferritins and proteins associated with glutathione synthesis (16) . Although cribrostatin 6 has been shown to affect the viability of cancer cell lines, its selectivity for cancer cells over normal cells has never been demonstrated. Such selectivity is seldom explored, yet is increasingly seen as a critical property of compounds proposed as potential cancer therapeutics.
Given its mechanism of action and the demonstrated susceptibility of cancer cells to additional oxidative stress, we sought to generate a more potent analogue of cribrostatin 6, with the aim of improving both the potency and cancer cell selectivity. There have been several reported total syntheses of cribrostatin 6 (17) (18) (19) (20) (21) . We chose to adapt a modular route that we had developed as it facilitated the rapid incorporation of a variety of substituents on carbons 8 and 9 of the isoquinoline ring and was readily adapted to reverse the positioning of these alkyl and alkoxy residues (Scheme 1) (20) .
Thus, the brominated core, imidazo[1,5-a]pyridine 4, was prepared in three steps from 3-bromo-2-cyanopyridine 1 as previously described (20) . Contemporaneously, a series of cyclobutenediones 8 were prepared as surrogates for the quinone ring each bearing alkoxy and organyl residues at C3 and C4 respectively. Syntheses of cribrostatin 6 and analogues B-K were then achieved by halogen-lithium exchange of 4, addition of the resulting aryllithium 9 to a cyclobutenedione 8 and thermolysis of the resulting adduct 7 with aerial oxidation. To achieve a synthesis of analogue A, in which the positions of the alkyl and alkoxy residues are swapped, required a subtle change of strategy. In this case the simple expedient of switching from organolithium intermediate 9 to organoytterbium ate complex 11 changed the course of nucleophilic addition in favor of addition to the vinylogous ester carbonyl C3 (22) . Thermolysis of the resulting adduct 10 followed by aerial oxidation then gave analogue A.
The effect of cribrostatin 6 and analogues A-K on the viability of MCF7 breast cancer cells was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Table 1 and Supplementary Figure 1-12) . The most potent molecule was analogue D (IC 50 of 428 ± 40 nM) with a phenyl ring on C8 in place of the methyl residue found in the parent molecule ( Figure 1A , from hereon referred to as 8PC6, for 8-phenylcribrostatin 6). This substitution resulted in a 30% increase in potency against MCF7 breast cancer cells compared to cribrostatin 6 (IC 50 of 628 ± 67 nM). With a more potent analogue in hand, we assessed the effect of 1 µM 8PC6 on a number of cancer and non-cancer cell lines from a variety of tissue types ( Figure 1B) .
As a comparison, we also assessed the effect of 1 µM cribrostatin 6 in the same panel of cells (Figure 1 ). 8PC6 was more potent than cribrostatin 6 in all cases, with a greater effect on the viability of the cancer cell lines (reduced to 16-28%) than normal cells (reduced to 69-88%). The selectivity of cribrostatin 6 for the cancer cell lines in our panel (reduced to 36-54%) over normal cells (viability reduced to 69-87%) was less pronounced at this dose ( Figure 1 ). The IC 50 of 8PC6 was next determined by MTT assay in each of these cell lines ( Table   2 , and Supplementary Figure 20 -26) . The IC 50 of 8PC6 was found to be ca. four-fold higher in non-cancer cell lines (average IC 50 of 1.8 µM) than that in cancer cell lines (average IC 50 of 480 nM). In addition, 8PC6 was more potent than its parent molecule in every cell line (Table 2 ). The effect of 8PC6 on intracellular ROS levels was next probed using the ROS-sensing dye 2',7'-dichlorofluorescin diacetate (DCFDA) (3, 23) . The mechanism of action of 8PC6 was next probed. The generation of superoxide by quinones requires molecular oxygen (8) , and as 8PC6 is proposed to function through a similar mechanism, its potency is expected to be reduced in cells pre-incubated in a hypoxic environment. It should be noted that while hypoxia leads to a short-term increase in basal ROS in cells (6, 26) , the decrease in molecular oxygen levels within these cells means that ROS generation by 8PC6 and its subsequent effect on cell viability would be expected to be reduced. Figure 31) .
Conclusions
Our findings demonstrate that 8PC6 and cribrostatin 6 selectively inhibit the growth of cancer cells via elevation of intracellular ROS. Work is currently underway in our laboratories to further probe the mechanism and effect of 8PC6 in other cell lines, and we are continuing to synthesize and assess additional derivatives of this molecule.
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